Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en SciELO
Compartir
Revista Científica Ciencia Médica
versión impresa ISSN 2077-3323
Resumen
LOPEZ BASCOPE, Eonice et al. METFORMIN IN THE POLYCYSTIC OVARIAN SYNDROME TREATMENT. A RANDOMIZED CLINICAL TRIAL. Rev Cient Cienc Méd [online]. 2017, vol.20, n.2, pp.45-52. ISSN 2077-3323.
Background: Polycystic ovary syndrome is the most frequent cause of anovulatory infertility, characterized by menstrual irregularities, signs of androgen excess, obesityand insulin resistance. Objective: To evaluate the inclusion of sensitizers as metformin, in the treatment of Polycystic ovary syndrome, combined with combined oral contraceptives, versus monotherapy with combined oral contraceptives Materials and methods: A randomized clinical trial was conducted with 60 women aged ≥18 years, divided into 2 homogeneous groups of 30 patients: one received monotherapy with combined oral contraceptives and another received combined treatment of the contraceptives with Metformin. The treatment was performed during 3 cycles of 3 months each. The therapeutic equivalence was compared using the Student's T test for independent samples. Bivariate logistic regression and multimonial logistic regression were used to obtain crude and adjusted Odds Ratio. Results: Average time of remission of the clinic sintoms was lower in the combined therapy, with 3,07 ± 0,21 months for Oligomenorrhea, 3,07 ± 0,21 months for acne, and 7,52 ± 0,42 months for hirsutism; the difference between the means of clinical remission was statistically significant for oligomenorrhea (p = 0,02) and acne (p = 0,001). The mean time of remission by ultrasound was lower in the group receiving combination therapy (6,7 ± 0,23 months), this difference being statistically significant (p = <0,001). Conclusion: Combined treatment of Polycystic ovary syndrome with combined oral contraceptives + Metformin (500mg/day), favors a shorter ultrasound remission, as well as the associated symptoms, and a lower rate of recurrence at 3 months.
Palabras clave : Randomized Controlled Trial; Polycystic Ovary Syndrome; Metformin.